顾倩,李春坚

• 1:南京医科大学第一附属医院心内科

摘要(Abstract)：

抗血小板治疗可有效减少急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗术后血栓事件,但同时也增加了出血风险。目前国内外多个出血评分系统可用于预测ACS患者在不同时期的出血风险,有助于个体化抗血小板治疗的决策。本文对REPLACE、Mehran、CRUSADE、HASBLED、ACTION、DAPT、PARIS、PRECISE-DAPT、BleeMACS、BRIC-ACS评分系统的定义及应用作一综述,为临床应用提供参考。

关键词(KeyWords)： 急性冠状动脉综合征;抗血小板治疗;出血风险评分

Abstract:

Keywords:

基金项目(Foundation): 江苏省科教强卫工程医学重点人才项目（ZDRCA2016013）;; 2019年江苏省研究生实践创新计划（SJCX19_0420）

作者(Author): 顾倩,李春坚

参考文献(References)：

• [1]Mauri L,Hsieh WH,Massaro JM,et al.Stent thrombosis in randomized clinical trials of drug-eluting stents.N Engl J Med,2007,356(10):1020-1029.
• [2]Bittl JA,Baber U,Bradley SM,et al.Duration of dual antiplatelet therapy:a systematic review for the 2016 ACC/AHA guideline f ocused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.Circulation,2016,134(10):e156-e178.
• [3]Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines f or the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force f or the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J,2016,37(3):267-315.
• [4]Bagai A,Bhatt DL,Eikelboom JW,et al.Individualizing duration of dual antiplatelet therapy af ter acute coronary syndrome or percutaneous coronary intervention.Circulation,2016,133(21):2094-2098.
• [5]Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.Eur J Cardiothorac Surg,2018,53(1):34-78.
• [6]Wang Y,Wang Y,Zhao X,et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.N Engl J Med,2013,369(1):11-19.
• [7]Wang Y,Pan Y,Zhao X,et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial:oneyear outcomes.Circulation,2015,132(1):40-46.
• [8]Furtado RHM,Nicolau JC,Magnani G,et al.Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting:insights from PEGASUS-TIMI54.Eur Heart J,2020,41(17):1625-1632.
• [9]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [10]Mehran R,Giustino G,Baber U.DAPT duration after DES:what is the“mandatory”duration?J Am Coll Cardiol,2015,65(11):1103-1106.
• [11]Steg PG,Huber K,Andreotti F,et al.Bleeding in acute coronary syndromes and percutaneous coronary interventions:position paper by the working group on thrombosis of the European Society of Cardiology.Eur Heart J,2011,32(15):1854-1864.
• [12]Amin AP,Bachuwar A,Reid KJ,et al.Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status.J Am Coll Cardiol,2013,61(21):2130-2138.
• [13]Chhatriwalla AK,Amin AP,Kennedy KF,et al.Association bet ween bleed ing even ts a nd in-hospital mor talit y af ter percutaneous coronary intervention.JAMA,2013,309(10):1022-1029.
• [14]Valgimigli M,Costa F,Lokhnygina Y,et al.Tradeoff of myocardial inf arction vs.bleeding types on mortality af ter acute coronary syndrome:lessons f rom the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial.Eur Heart J,2017,38(11):804-810.
• [15]Nikolsky E,Mehran R,Dangas G,et al.Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.Eur Heart J,2007,28(16):1936-1945.
• [16]Lincoff AM,Bittl JA,Kleiman NS,et al.Comparison of bivalirudin versus heparin during percutaneous coronary intervention(the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events[REPLACE]-1 trial).Am J Cardiol,2004,93(9):1092-1096.
• [17]Lincoff AM,Kleiman NS,Kereiakes DJ,et al.Long-term effi cacy of bivalirudin and provisional glycoproteinⅡb/Ⅲa blockade vs.heparin and planned glycoproteinⅡb/Ⅲa blockade during percutaneous coronary revascularization:REPLACE-2 randomized trial.JAMA,2004,292(6):696-703.
• [18]Mehran R,Pocock SJ,Nikolsky E,et al.A risk score to predict bleeding in patients with acute coronary syndromes.J Am Coll Cardiol,2010,55(23):2556-2566.
• [19]Stone GW,White HD,Ohman EM,et al.Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention:a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.Lancet,2007,369(9565):907-919.
• [20]Stone GW,Bertrand ME,Moses JW,et al.Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:the ACUITY timing trial.JAMA,2007,297(6):591-602.
• [21]Stone GW,Witzenbichler B,Guagliumi G,et al.Bivalirudin during primary PCI in acute myocardial infarction.N Engl J Med,2008,358(21):2218-2230.
• [22]Subherwal S,Bach RG,Chen AY,et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE (can rapid risk stratifi cation of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines)bleeding score.Circulation,2009,119(14):1873-1882.
• [23]Abu-Assi E,Gracía-Acuna JM,Ferreira-González I,et a l.Evaluating the performance of the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction.Circulation,2010,121(22):2419-2426.
• [24]Abu-Assi E,Raposeiras-Roubin S,Lear P,et al.Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome.Eur Heart J Acute Cardiovasc Care,2012,1(3):222-231.
• [25]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTSguidelines on myocardial revascularization:the task f orce on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThor acic Su rger y (EACTS) develo ped wit h t he special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).Eur Heart J,2014,35(37):2541-2619.
• [26]Kadakia MB,Desai NR,Alexander KP,et al.Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial inf arction:a report f rom the NCDR ACTIONRegistry--GWTG (national cardiovascular data registry acute coronary treatment and intervention outcomes network registry--get with the guidelines).JACC Cardiovasc Interv,2010,3(11):1166-1177.
• [27]Costa F,Tijssen JG,Ariotti S,et al.Incremental Value of the CRUSADE,ACUITY,and HAS-BLED risk scores f or the prediction of hemorrhagic events af ter coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy.J Am Heart Assoc,2015,4(12):e002524.
• [28]Choi SY,Kim MH,Cho YR,et al.Performance of PRECISE-DAPT score for predicting bleeding complication during dual antiplatelet therapy.Circ Cardiovasc Interv,2018,11(12):e006837.
• [29]Faustino A,Mota P,Silva J.Non-ST-elevation acute coronary syndromes in octogenarians:applicability of the GRACEand CRUSADE scores.Rev Port Cardiol,2014,33(10):617-627.
• [30]Mischie AN,Andrei CL,Sinescu C,et al.Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome.J Geriatr Cardiol,2017,14(7):442-456.
• [31]Pisters R,Lane DA,Nieuwlaat R,et al.A novel user-friendly score(HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey.Chest,2010,138(5):1093-1100.
• [32]Mathews R,Peterson ED,Chen AY,et al.In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care:derivation and validation of a model f rom the ACTIONRegistry(R)-GWTG.Am J Cardiol,2011,107(8):1136-1143.
• [33]Yeh RW,Secemsky EA,Kereiakes DJ,et al.Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year af ter percutaneous coronary intervention.JAMA,2016,315(16):1735-1749.
• [34]Camenzind E,Wijns W,Mauri L,et al.Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation:a randomised,multicentre,open-label,controlled trial.Lancet,2012,380(9851):1396-1405.
• [35]Song L,Guan C,Yan H,et al.Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome af ter drugeluting stent implantations.Catheter Cardiovasc Interv,2018,91(S1):573-581.
• [36]Baber U,Mehran R,Giustino G,et al.Coronary thrombosis and major bleeding after PCI with drug-eluting stents:risk scores from PARIS.J Am Coll Cardiol,2016,67(19):2224-2234.
• [37]Stone GW,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):a prospective multicentre registry study.Lancet,2013,382(9892):614-623.
• [38]Costa F,van Klaveren D,James S,et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT) score:a pooled analysis of individualpatient datasets from clinical trials.Lancet,2017,389(10073):1025-1034.
• [39]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl JMed,2009,361(11):1045-1057.
• [40]Zanchin T,Raber L,Koskinas KC,et al.Preprocedural highsensitivity cardiac troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention.Circ Cardiovasc Interv,2016,9(6):e003202.
• [41]Raposeiras-Roubín S,Faxén J，í?iguez-Romo A,et al.Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome:the Blee MACS score.Int JCardiol,2018,254:10-15.
• [42]Jernberg T,Attebring MF,Hambraeus K,et al.The Swedish Websystem for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies(SWEDEHEART).Heart,2010,96(20):1617-1621.
• [43]Manzano-Fernández S,Sánchez-Martínez M,Flores-Blanco PJ,et al.Comparison of the global registry of acute coronary events risk score versus the can rapid risk stratifi cation of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines risk score to predict in-hospital mortality and major bleeding in acute coronary syndromes.Am J Cardiol,2016,117(7):1047-1054.
• [44]Ariza-SoléA,Formiga F,Lorente V,et al.Effi cacy of bleeding risk scores in elderly patients with acute coronary syndromes.Rev Esp Cardiol (Engl Ed),2014,67(6):463-470.
• [45]Koller L,Rothgerber DJ,Sulzgruber P,et al.History of previous bleeding and C-reactive protein improve assessment of bleeding risk in elderly patients（≥80 years) with myocardial infarction.Thromb Haemost,2015,114(5):1085-1091.
• [46]Garay A,Ariza-SoléA,Formiga F,et al.Prediction of post-discharge bleeding in elderly patients with acute coronary syndromes:insights f rom the Blee MACS registry.Thromb Haemost,2018,11895:929-938.
• [47]Chen Y,Yin T,Xi S,et al.A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention:BRIC-ACS study.Catheter Cardiovasc Interv,2019,93(7):1194-1204.
• [48]Généreux P,Giustino G,Witzenbichler B,et al.Incidence,predictors,a nd im pact of post-discha rge bleeding af ter percutaneous coronary intervention.J Am Coll Cardiol,2015,66(9):1036-1045.
• [49]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南（2016）.中华心血管病杂志，2017,45(5):359-376.
• [50]Kirchhof P,Lip GYH,Camm AJ,et al.Guidelines for the management of atrial fi brillation:the task force for the management of atrial fi brillation of the European Society of Cardiology (ESC).Eur Heart J,2010,31(19):2369-2429.
• [51]Hindricks G,Potpara T,Dagres N,et al.2020 ESC guidelines f or t he d ia g nosis a nd ma na geme n t of a t r ia l f i br illa t ion developed in collaboration with the European Association f or Cardio-Thoracic Surgery(EACTS):the task f orce f or the diagnosis and management of atrial f ibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC.Eur Heart J,2021,42(5):373-498.
• [52]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline f ocused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol,2016,68(10):1082-1115.